Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

NIAID halts Lilly COVID-19 antibody study

By Brian Buntz | October 27, 2020

An arm of NIH has ended a clinical trial investigating the use of Eli Lilly’s (NYSE:LLY) monoclonal antibody LY-CoV555 (bamlanivimab) to treat hospitalized COVID-19 patients.

In separate news, HHS plans to allocate 300,000 doses of the monoclonal antibody immediately, according to an announcement.

While the drug shows promise in treating mild-to-moderate COVID-19 infections, the ACTIV-3 trial involving severe cases of the disease showed little benefit, according to the National Institute of Allergy and Infectious Diseases (NIAID).

The study, which involved 326 participants, involved hospitalized patients treated with 7000 mg of bamlanivimab. In a statement, Lilly acknowledged that “hospitalized patients may have less benefit from neutralizing antibodies” than those with less-severe COVID-19 infections.

Results from BLAZE-1, an ongoing Phase 2 trial for patients recently diagnosed with COVID-19 in an outpatient setting, have been more encouraging. Patients in that trial exhibited reduced viral load and symptoms, according to the company. In a statement, the company said it is “confident” based on preliminary data that bamlanivimab monotherapy “may prevent progression of disease for those earlier in the course of COVID-19.”

BLAZE-1 combined bamlanivimab with the antiviral remdesivir, which FDA recently approved as a COVID-19 treatment.

Lilly has filed for FDA emergency use authorization to use bamlanivimab and Olumiant, a rheumatoid arthritis therapy, to treat patients with SARS-CoV-2 infections.

This story was originally published on Oct. 27, and updated on Nov. 10. 


Filed Under: clinical trials, Drug Discovery
Tagged With: bamlanivimab, coronavirus, covid-19, Eli Lilly & Co., LY-CoV555
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50